# Vasopressor Weaning

Wean vasopressors only after sustained perfusion and correction of the shock driver, using protocolized dose reductions with MAP monitoring. In septic shock receiving norepinephrine plus vasopressin, discontinuation order remains uncertain; avoid treating either sequence as mortality-determining.

**Clinical question:** How should clinicians safely taper intravenous vasopressors after shock stabilization, and does discontinuation order matter?

Updated: 2026-09-15T18:18:21.619296+00:00

## What matters in practice
- Begin intravenous vasopressor reduction only after MAP is greater than 65 mmHg on a stable dose; a protocolized approach reduces the stabilizing dose by at least 25% at intervals of 4 hours or less while maintaining MAP at least 65 mmHg. [16]
- For septic shock, norepinephrine is the primary vasopressor and vasopressin is an adjunct used to raise MAP or reduce norepinephrine exposure; the norepinephrine dose that should trigger vasopressin remains variable in practice. [8][17]
- Stopping vasopressin before norepinephrine has been associated with more rebound hypotension in pooled observational data, but available studies show no significant ICU or in-hospital mortality difference by discontinuation order. [7][20]
- Do not use enteral midodrine routinely to expedite liberation from intravenous vasopressors; its ICU use is off-label, randomized evidence is mixed, and bradycardia is a relevant adverse effect. [1][10][11]
- In cardiogenic shock, assess readiness for daily de-escalation by hemodynamic stability, total vasoactive requirement, volume status, and correction or improvement of the underlying cause; refractory patients should prompt shock-center consultation or transfer consideration. [2]

## Confirm recovery rather than treating a transient MAP response

Use vasopressor reduction as a bedside test of whether vascular tone and forward flow are now adequate.

Before decreasing an infusion, confirm that MAP is greater than 65 mmHg on a stable vasopressor dose. The CLOVERS protocol targeted MAP 65 to 75 mmHg and initiated weaning only after MAP exceeded 65 mmHg on a stable dose; use recurrent MAP below 65 mmHg during tapering as a trigger to restore the prior effective dose and reassess the cause of instability. [16]

Do not interpret a normal MAP alone as recovery from shock. Reassess the original hemodynamic defect and the current response to volume management before tapering: passive-leg-raise-induced stroke-volume change can identify fluid responsiveness, while capillary refill time provides a noninvasive peripheral perfusion target. These approaches support individualized resuscitation rather than empiric fluid administration for every hypotensive episode. [9]

In cardiogenic shock, conduct a daily readiness assessment that includes hemodynamic stability, aggregate vasoactive support, volume status, and whether the precipitating cause has been corrected or improved. Failure to stabilize on initial pharmacologic support should prompt consultation with, or transfer consideration to, a Level 1 cardiogenic-shock center for temporary mechanical circulatory support or advanced therapies. [2]
- Proceed with a taper when MAP is greater than 65 mmHg on a stable infusion rate. [16]
- Pause or reverse the taper for recurrent MAP below 65 mmHg, then reassess fluid responsiveness, peripheral perfusion, and the unresolved shock driver. [9][16]
- For cardiogenic shock, do not pursue serial weaning attempts without reconsidering revascularization, structural correction, or temporary mechanical circulatory support when vasoactive requirements remain refractory. [2]

*Readiness elements that determine whether vasopressor reduction is appropriate. [2][9][16]*

| Domain | Bedside assessment | Action if unfavorable |
| --- | --- | --- |
| Arterial pressure | MAP greater than 65 mmHg on a stable dose. [16] | Maintain or return to the prior effective infusion dose if MAP falls below 65 mmHg during taper. [16] |
| Volume responsiveness | Assess stroke-volume response to passive leg raise when deciding whether further fluid is likely to help. [9] | Avoid reflex fluid boluses when testing does not support fluid responsiveness; reassess the cause of hypotension. [9] |
| Peripheral perfusion | Use serial capillary refill time as a dynamic perfusion measure. [9] | Persistent abnormal peripheral perfusion warrants reassessment of resuscitation and shock physiology before further tapering. [9] |
| Cardiogenic shock recovery | Review hemodynamic stability, vasoactive requirement, volume status, and correction of the underlying cause daily. [2] | Escalate to shock-center consultation or transfer consideration if refractory to initial pharmacologic therapy. [2] |

## Use small, protocolized reductions with a defined MAP floor

A reproducible weaning schedule prevents prolonged exposure while making recurrent hypotension immediately interpretable.

For a patient who meets readiness criteria, reduce the active vasopressor by at least 25% of the stabilizing dose at intervals no longer than 4 hours, maintaining MAP at least 65 mmHg. This is a pragmatic protocolized method used in CLOVERS; it provides a concrete default when local ICU policy does not specify a taper rate. [16]

Continue close arterial-pressure surveillance during each reduction. A hypotensive response is not simply a failed wean: it should prompt reassessment for persistent vasodilation, inadequate intravascular volume, or impaired cardiac output using the same hemodynamic framework that guided resuscitation. Passive-leg-raise stroke-volume testing and capillary refill reassessment can help distinguish a potentially fluid-responsive state from one requiring another strategy. [9]

Avoid using prolonged low-dose infusion as a substitute for reassessment of shock etiology. In cardiogenic shock, selection and dose of vasoactive therapy should reflect the dominant hemodynamic pattern; norepinephrine is a reasonable first choice for most hypotensive patients, whereas dobutamine and milrinone increase cardiac output but may lower or leave blood pressure unchanged. [2]
- Set the operational target before each dose change: MAP at least 65 mmHg. [16]
- Reduce by at least 25% of the stabilizing dose no less frequently than every 4 hours when stable. [16]
- If MAP falls, stop further down-titration and reassess volume responsiveness and peripheral perfusion rather than automatically giving fluid. [9][16]

### Cardiogenic shock: align the taper with the hemodynamic phenotype

When hypotension remains the dominant problem in cardiogenic shock, norepinephrine is a reasonable first-line agent; the ACC dosing range is 0.05 to 1 microgram/kg/min. If low cardiac output persists despite adequate pressure, dobutamine 2 to 10 microgram/kg/min or milrinone 0.125 to 0.5 microgram/kg/min may improve cardiac output but can reduce systemic vascular resistance and blood pressure, so tapering a vasopressor before reassessing the need for inotropic support can unmask hypotension. [2]

For patients requiring temporary mechanical circulatory support, reassess weaning readiness daily rather than applying a fixed duration. The critical questions are whether pharmacologic support is decreasing, volume status is acceptable, and the cardiac insult has improved or been corrected. [2]
- Norepinephrine: 0.05 to 1 microgram/kg/min in cardiogenic shock. [2]
- Dobutamine: 2 to 10 microgram/kg/min; increases cardiac output but may lower blood pressure. [2]
- Milrinone: 0.125 to 0.5 microgram/kg/min; increases cardiac output but may lower blood pressure. [2]

*Selected vasoactive doses and hemodynamic implications relevant to de-escalation in cardiogenic shock. [2]*

| Agent | Dose | Expected hemodynamic effect | Weaning implication |
| --- | --- | --- | --- |
| Norepinephrine | 0.05-1 microgram/kg/min. [2] | Raises systemic vascular resistance, blood pressure, and cardiac output. [2] | Reasonable first-line agent for most hypotensive cardiogenic-shock patients. [2] |
| Vasopressin | 0.01-0.04 units/min. [2] | Raises systemic vascular resistance and blood pressure with little effect on heart rate. [2] | Use the ongoing pressure response and overall vasoactive requirement to guide de-escalation. [2] |
| Dobutamine | 2-10 microgram/kg/min. [2] | Increases cardiac output; systemic vascular resistance and blood pressure may decrease or remain unchanged. [2] | Do not reduce pressure support without considering whether persistent low output remains the limiting physiology. [2] |
| Milrinone | 0.125-0.5 microgram/kg/min. [2] | Increases cardiac output while lowering systemic vascular resistance and blood pressure. [2] | Hypotension during vasopressor taper may reflect the inodilator effect rather than recovery failure alone. [2] |

## Which agent should be stopped first when norepinephrine and vasopressin are running?

The immediate endpoint is maintenance of MAP, not adherence to a discontinuation sequence.

In septic shock, norepinephrine remains the primary vasopressor and vasopressin is used as an adjunct to increase MAP or reduce norepinephrine dose. Guidance cited in the literature supports vasopressin up to 0.03 units/min for these purposes, but does not define a single norepinephrine threshold for initiating vasopressin; local practice therefore varies substantially. [7][8][17]

For patients receiving both agents, the discontinuation order is unsettled. A meta-analysis of nine studies involving 1,245 patients found a higher risk of hypotension when vasopressin was withdrawn before norepinephrine. Another systematic review and meta-analysis included five studies and 930 patients, but pooled ICU mortality was not significantly different between norepinephrine-first and vasopressin-first groups (risk ratio 1.11, 95% CI 0.79-1.56), nor was in-hospital mortality significantly different (risk ratio 1.22, 95% CI 0.86-1.74). [7][20]

The clinical literature is conflicting at the patient-level and trial level: a small randomized trial stopped early after enrolling 85 patients reported nearly threefold more hypotension at 1 hour with norepinephrine-first than vasopressin-first tapering, whereas a cohort of more than 500 patients found no difference in hypotension within 24 hours. Use the sequence that allows incremental reduction with immediate MAP rescue; do not claim a proven survival advantage for either sequence. [8]
- Use norepinephrine as the primary septic-shock vasopressor; add vasopressin to increase MAP or reduce norepinephrine exposure. [8]
- If vasopressin is stopped first, anticipate possible rebound hypotension and monitor MAP closely. [7][20]
- Do not select a discontinuation sequence on the expectation of reduced ICU or hospital mortality. [20]

*Evidence-informed approach to norepinephrine-vasopressin discontinuation in septic shock. [7][8][20]*

| Clinical situation | Interpretation | Practical action |
| --- | --- | --- |
| MAP remains above 65 mmHg on stable dual therapy. [16] | The patient meets a minimum pressure criterion for a monitored taper. [16] | Reduce one agent using protocolized steps and maintain MAP at least 65 mmHg. [16] |
| Vasopressin is considered for discontinuation first. | Pooled data associate vasopressin-first discontinuation with more hypotension, while mortality differences have not been demonstrated. [7][20] | Use close MAP surveillance and restore effective support promptly if hypotension occurs. [16] |
| Norepinephrine is considered for discontinuation first. | A small randomized trial suggested more early hypotension with this sequence, but larger observational findings are discordant. [8] | Do not assume the sequence is unsafe; use incremental changes and reassess the patient-specific shock physiology. [8][16] |
| Clinically important rebound hypotension occurs. | Discontinuation order studies do not establish a mortality benefit for either sequence. [20] | Resume or increase the prior effective vasopressor support and reassess perfusion and fluid responsiveness. [9][16] |

## Reserve midodrine or droxidopa for selected off-label situations

Enteral vasopressor-sparing strategies should not replace correction of the shock process or monitored intravenous support.

Midodrine is an oral alpha-1 agonist approved for orthostatic hypotension and increasingly used off-label to facilitate intravenous vasopressor liberation in sepsis and other resolving shock states. A pragmatic sepsis trial is evaluating enteral midodrine 10 mg three times daily, underscoring that its role in sepsis-associated hypotension remains under active study rather than established routine care. [1]

Trial regimens have included midodrine 20 mg three times daily in patients on stable vasopressors for more than 24 hours and 10 mg three times daily in smaller weaning studies. However, a prospective randomized trial using fixed-dose 20 mg every 8 hours did not expedite vasopressor discontinuation, whereas retrospective experience with every-6-hour dosing suggested more frequent reduction in intravenous vasopressor requirements within 24 hours. These conflicting data do not establish a preferred dose or schedule for ICU weaning. [10][11]

If midodrine is used, document its off-label intent, use it only after enteral absorption is feasible and the patient is otherwise in a resolving phase, and monitor for bradycardia. Do not delay escalation of intravenous support or definitive treatment of recurrent shock in order to continue an oral-agent trial. [1][11]

Droxidopa is another emerging off-label enteral option; systematic-review findings suggest it may facilitate vasopressor weaning, but dosing and study approaches vary. It should therefore be reserved for individualized specialist-directed use rather than protocolized first-line liberation. [3][4]
- Midodrine ICU vasopressor liberation is off-label. [1]
- Studied midodrine regimens include 10 mg three times daily and 20 mg every 8 hours or three times daily; evidence does not define a routine regimen. [1][10][11]
- Monitor for bradycardia if midodrine is used. [11]
- Consider droxidopa investigational for this purpose because dose and efficacy data remain heterogeneous. [3][4]

*Enteral agents considered for intravenous vasopressor liberation. [1][3][4][10][11]*

| Agent | Status and studied use | Decision point | Important limitation |
| --- | --- | --- | --- |
| Midodrine | Approved for orthostatic hypotension; ICU use to facilitate vasopressor weaning is off-label. Studied regimens include 10 mg three times daily and 20 mg every 8 hours or three times daily. [1][10][11] | Consider only in selected patients with resolving shock and feasible enteral administration. [1][11] | Randomized and observational results conflict; bradycardia is a relevant adverse effect. [10][11] |
| Droxidopa | Off-label emerging approach for vasopressor weaning. [3][4] | Reserve for individualized use rather than routine ICU protocol implementation. [3][4] | Published findings vary in dosing and study design. [3][4] |

## Treat recurrent hypotension during weaning as persistent shock

Repeated failure should trigger re-phenotyping, not indefinite cycling of infusion rates.

When MAP cannot be maintained at 65 mmHg after a dose reduction, restore the last effective vasopressor dose and reassess whether the patient is fluid responsive using passive leg raise with stroke-volume measurement. A positive dynamic response supports a fluid-responsive physiology; a nonresponsive result argues against routine additional fluid and requires reassessment of vascular tone and cardiac output. [9][16]

For septic shock on norepinephrine and vasopressin, recurrent hypotension after stopping either agent should be managed as a hemodynamic event rather than attributed solely to the sequence. The literature shows discordant sequence findings and no demonstrated ICU or in-hospital mortality difference, so the next action is restoration of adequate pressure and renewed assessment of the underlying physiology. [8][20]

For cardiogenic shock with persistent or rising vasoactive needs despite initial pharmacologic treatment, contact a Level 1 cardiogenic-shock center and consider transfer for temporary mechanical circulatory support and advanced therapies. Daily reassessment should include whether the causal lesion or insult has been corrected and whether total pharmacologic support is falling. [2]
- MAP below 65 mmHg during taper: restore effective support, pause further tapering, and reassess. [16]
- Use passive leg raise with stroke-volume assessment to decide whether fluid is likely to improve hemodynamics. [9]
- Refractory cardiogenic shock: pursue shock-center consultation or transfer consideration rather than serial vasoactive adjustments alone. [2]

*Response to common vasopressor-weaning failures. [2][9][16][20]*

| Failure pattern | Immediate response | Next discriminating assessment |
| --- | --- | --- |
| MAP falls below 65 mmHg after a decrement. [16] | Return to the prior effective dose and stop further weaning. [16] | Assess fluid responsiveness with passive leg raise and stroke-volume measurement; reassess capillary refill. [9] |
| Repeated instability while receiving norepinephrine plus vasopressin. | Restore the agent or dose that maintained adequate MAP. [16] | Do not infer a mortality-relevant error from sequence alone; pooled mortality differences are not significant. [20] |
| Persistent cardiogenic-shock vasoactive requirement. | Reassess the need for ongoing vasoactive and mechanical support daily. [2] | Determine whether volume status and the underlying cause have improved; seek Level 1 shock-center input if refractory. [2] |

## References
1. Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial | BMJ Open — bmjopen.bmj.com — https://bmjopen.bmj.com/content/16/4/e117846
2. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.02.018
3. Review Article Droxidopa in Critical Care - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1155/ccrp/4830160
4. Droxidopa in Critical Care: A Systematic Review of an Emerging Off ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1155/ccrp/4830160
5. Catecholamine Vasopressor Support Sparing Strategies in ... — accpjournals.onlinelibrary.wiley.com — https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.2199
6. Catecholamine Vasopressor Support Sparing Strategies in ... - Ovid — accpjournals.onlinelibrary.wiley.com — https://accpjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2199
7. Effects of the discontinuation sequence of norepinephrine and vasopressin on hypotension incidence in patients with septic shock: A meta-analysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0147956319301153
8. Vasopressor weaning in sepsis: Debate is being continued! : Journal of Anaesthesiology Clinical Pharmacology — journals.lww.com — https://journals.lww.com/joacp/fulltext/2023/39030/vasopressor_weaning_in_sepsis__debate_is_being.25.aspx
9. Why Has Biomarker-Guided Fluid Resuscitation for... : Critical Care Explorations — journals.lww.com — https://journals.lww.com/ccejournal/fulltext/2025/06000/why_has_biomarker_guided_fluid_resuscitation_for.8.aspx
10. Hemodynamic Effects of an Increased Midodrine Dosing... : Critical Care Explorations — journals.lww.com — https://journals.lww.com/ccejournal/fulltext/2021/04000/hemodynamic_effects_of_an_increased_midodrine.24.aspx
11. Adjunctive Midodrine Therapy for... : Critical Care Medicine — journals.lww.com — https://journals.lww.com/ccmjournal/fulltext/2025/02000/adjunctive_midodrine_therapy_for.12.aspx
12. 2023 ACCP Annual Meeting November 11 ‐ 14, 2023 — accpjournals.onlinelibrary.wiley.com — https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.1903?AllField=seminars+dialysis&af=R&content=articlesChapters&mi=49buyt&target=default
13. Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0883944113001755
14. Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0883944119318490
15. [PDF] Clinical management of severe acute respiratory infection when ... — iris.who.int — https://iris.who.int/server/api/core/bitstreams/64c41acd-7e6d-4725-9dfe-ed2ba465ecef/content
16. [PDF] Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/28/NCT03434028/Prot_000.pdf
17. [PDF] VASSPR-Study protocol v1.1A (clean) - ClinicalTrials.gov — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/62/NCT06217562/SAP_001.pdf
18. [PDF] The MENDS II Study Maximizing the Efficacy of ... - ClinicalTrials.gov — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/33/NCT01739933/Prot_000.pdf
19. Comparison of vasopressin-first weaning versus norepinephrine-first weaning in critically ill patients — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12825015
20. Incidence of Hypotension after Discontinuation of Norepinephrine or Arginine Vasopressin in Patients with Septic Shock: a Systematic Review and Meta-Analysis - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6942129

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.